Loading...
•
Jun 30, 2023
Sana Q2 2023 Earnings Report
Sana Biotechnology reported financial results and business highlights.
Key Takeaways
Sana Biotechnology reported its Q2 2023 financial results, highlighting the continued progress in their clinical programs, particularly the ARDENT trial for SC291 in B-cell malignancies, and the expectation of initial data from two clinical studies later in the year. The company's cash position is expected to support activities through multiple data readouts and last into 2025.
Continued enrollment in the ARDENT Phase 1 study evaluating SC291 in patients with B-cell malignancies, with initial data expected this year.
Expect initial data later this year from an investigator-sponsored trial with hypoimmune-modified primary human islet cells for type 1 diabetes patients.
Goal to submit INDs this year for both SC262 and SG299 in hematologic cancers.
Strengthened R&D leadership with the addition of Dr. Doug Williams as President of Research and Development and Dr. Gary Meininger as Chief Medical Officer.
Forward Guidance
Sana Biotechnology is focused on creating and delivering engineered cells as medicines for patients. They anticipate progress in their clinical programs, particularly the ARDENT trial for SC291 in B-cell malignancies, and the expectation of initial data from two clinical studies later in the year.
Positive Outlook
- Enrollment in the ARDENT Phase 1 study continued.
- SC291 has the potential to serve as clinical proof-of-platform for other hypoimmune-modified CAR T cell candidates using clinically-validated or commercially-approved CAR constructs in development at Sana for hematological malignancies, such as SC262 (CD22) and SC255 (BCMA).
- Sana expects initial data later this year from an investigator-sponsored trial transplanting hypoimmune-modified primary human islet cells into type 1 diabetes patients.
- Sana’s goal is to file an IND for SC451 in 2024.
- Hypoimmune-modified iPSCs were differentiated into pancreatic islet cells. Transplantation of hypoimmune-modified iPSC-derived pancreatic cells into allogeneic diabetic mice with a humanized immune system showed immune evasion after transplantation for the duration of the studies (4 weeks) and amelioration of diabetes and normalization of blood glucose levels.
Challenges Ahead
- The value of these potential liabilities may fluctuate significantly with changes in Sana’s market capitalization and stock price.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...